Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
X-ray Crystallographic Studies of the Aminoglycoside Modifying Enzyme APH(2'')-Id and Its Inhibitors
FY 2009-10
Summary
Bacterial resistance to antibiotic therapy continues to be a significant threat to public health. Aminoglycosides represent an important class of antibiotics clinically used to treat severe bacterial infections. Gentamicin, for instance, is employed to treat septicemia, bone infections, respiratory tract infections, and urinary tract infections. Resistance to a number of aminoglycosides has been attributed to bacterial enzymes of the aminoglycoside-2''-phosphotransferase [APH(2'')] family, in the presence of which antibiotics are rendered ineffective and patients are greatly at risk. Among these proteins, APH(2'')-Id has been reported to confer high-level gentamicin-resistance. In principle, if the resistance mechanisms are inhibited, then the antibacterial activity of the aminoglycoside will be restored. This project aims to first solve the atomic crystal structure of APH(2'')-Id by X-ray crystallography, and then use this structural information as a basis for the rational design of small molecule inhibitors that specifically target this enzyme. Protein X-ray crystallography is considered the authoritative method of establishing the three-dimensional structure of a protein, which provides direct information on its modes of interaction with its natural binding partners. Having a detailed structural understanding of the aminoglycoside-modifying enzymes will help us in the design of either novel aminoglycosides immune to known resistance-conferring enzymes, or of specific inhibitors that can be co-administered with existing aminoglycosides, thereby alleviating persistent concerns about antibiotic resistance in clinical settings.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
206208
Name
Shi Kun
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
X-ray Crystallographic Studies of the Aminoglycoside Modifying Enzyme APH(2'')-Id and Its Inhibitors
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Aminoglycoside; Antibiotic Resistance; Aph(2'')-Id; Rational Drug Design; Structural Studies; X-Ray Crystallography
Abstract
Bacterial resistance to antibiotic therapy continues to be a significant threat to public health. Aminoglycosides represent an important class of antibiotics clinically used to treat severe bacterial infections. Gentamicin, for instance, is employed to treat septicemia, bone infections, respiratory tract infections, and urinary tract infections. Resistance to a number of aminoglycosides has been attributed to bacterial enzymes of the aminoglycoside-2''-phosphotransferase [APH(2'')] family, in the presence of which antibiotics are rendered ineffective and patients are greatly at risk. Among these proteins, APH(2'')-Id has been reported to confer high-level gentamicin-resistance. In principle, if the resistance mechanisms are inhibited, then the antibacterial activity of the aminoglycoside will be restored. This project aims to first solve the atomic crystal structure of APH(2'')-Id by X-ray crystallography, and then use this structural information as a basis for the rational design of small molecule inhibitors that specifically target this enzyme. Protein X-ray crystallography is considered the authoritative method of establishing the three-dimensional structure of a protein, which provides direct information on its modes of interaction with its natural binding partners. Having a detailed structural understanding of the aminoglycoside-modifying enzymes will help us in the design of either novel aminoglycosides immune to known resistance-conferring enzymes, or of specific inhibitors that can be co-administered with existing aminoglycosides, thereby alleviating persistent concerns about antibiotic resistance in clinical settings.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Shi, Kun
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~